Literature DB >> 20199975

Prognostic value of computed tomography morphologic characteristics in stage I non-small-cell lung cancer.

Inja Neralic Meniga1, Mirjana Kujundzic Tiljak, Davor Ivankovic, Ivan Aleric, Mirta Zekan, Pero Hrabac, Ivica Mazuranic, Igor Puljic.   

Abstract

BACKGROUND: In this study, we describe the prognostic value of NSCLC morphologic characteristics obtainable by computed tomography (CT) in the preoperative staging. Starting with the initial hypothesis that CT morphologic characteristics of NSCLC have a prognostic value, we conducted a retrospective study that included 194 patients. PATIENTS AND METHODS: All patients underwent surgery because of stage IA or IB non-small-cell lung carcinoma (NSCLC). Surgical procedures were performed in our clinic over the period of 9 years and 8 months starting in June 1996 and ending in February 2006. Preoperative CT scans and clinical data available for each patient were analyzed retrospectively.
RESULTS: Over the study period, 93 patients died. The mean survival time was 78.6 months (95% confidence interval was 72.63-84.57 months). After a 2-year follow-up, 85.57% of patients were alive, but this decreased to 63.9% living patients after 5 years. Morphologic tumor characteristics were obtained by analyzing CT images available for each patient. These CT morphologic characteristics were divided into 5 categories: size, tumor edges, structure, and periphery of the tumor, as well as its relation to visceral pleura. We correlated each of these characteristics to the survival of patients.
CONCLUSION: We conclude that, within stage I NSCLC, patient survival and disease prognosis vary significantly depending on such morphologic characteristics. This fact is one of the weakest points of the current tumor-node-metastasis (TNM) classification. Along with already-established tumor prognostic attributes such as size and TNM grade, we identified CT morphologic characteristics as powerful additional prognostic factors for NSCLC.

Entities:  

Mesh:

Year:  2010        PMID: 20199975     DOI: 10.3816/CLC.2010.n.013

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  6 in total

1.  Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Authors:  Kai-Hsiung Ko; Hsian-He Hsu; Tsai-Wang Huang; Hong-Wei Gao; Daniel H Y Shen; Wei-Chou Chang; Yi-Chih Hsu; Tsun-Hou Chang; Chi-Ming Chu; Ching-Liang Ho; Hung Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

2.  CT diagnosis of pleural and stromal invasion in malignant subpleural pure ground-glass nodules: an exploratory study.

Authors:  Qing Zhao; Jian-Wei Wang; Lin Yang; Li-Yan Xue; Wen-Wen Lu
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

3.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

4.  Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer.

Authors:  Kai-Hsiung Ko; Hsian-He Hsu; Tsai-Wang Huang; Hong-Wei Gao; Cheng-Yi Cheng; Yi-Chih Hsu; Wei-Chou Chang; Chi-Ming Chu; Jia-Hong Chen; Shih-Chun Lee
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

5.  Clinical Significance of Pleural Attachment and Indentation of Subsolid Nodule Lung Cancer.

Authors:  Hyung-Jun Kim; Jun Yeun Cho; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jin-Haeng Chung; Sukki Cho; Kwhanmien Kim; Kyung Won Lee; Jae Ho Lee; Choon-Taek Lee
Journal:  Cancer Res Treat       Date:  2019-03-25       Impact factor: 4.679

6.  Pathological components and CT imaging analysis of the area adjacent pleura within the pure ground-glass nodules with pleural deformation in invasive lung adenocarcinoma.

Authors:  Yining Jiang; Ziqi Xiong; Wenjing Zhao; Di Tian; Qiuping Zhang; Zhiyong Li
Journal:  BMC Cancer       Date:  2022-09-06       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.